NNMT Gene

NNMT Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">nnmt</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>NNMT</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Nicotinamide N-methyltransferase</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>11q13.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>4837</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000166741</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P40261</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>Parkinson's disease, Alzheimer's disease, cancer, metabolic disorders</td>
</tr>
<tr>
<td class="label">Metabolic Parameter</td>
<td>Normal</td>
</tr>
<tr>
<td class="label">NAD+ levels</td>
<td>Baseline</td>
</tr>
<tr>
<td class="label">SAM/SAH ratio</td>
<td>High</td>
</tr>
<tr>
<td class="label">MNAM levels</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Mitochondrial function</td>
<td>Normal</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>IC50</td>
</tr>
<tr>
<td class="label">JW-7</td>
<td>50 nM</td>
</tr>
<tr>
<td class="label">NAH-1</td>
<td>120 nM</td>
</tr>
<tr>
<td class="label">STL127709</td>
<td>200 nM</td>
</tr>
<tr>
<td class="label">SNP</td>
<td>Location</td>
</tr>
<tr>
<td class="label">rs6942</td>
<td>3'UTR</td>
</tr>
<tr>
<td class="label">

NNMT Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">nnmt</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>NNMT</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Nicotinamide N-methyltransferase</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>11q13.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>4837</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000166741</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P40261</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>Parkinson's disease, Alzheimer's disease, cancer, metabolic disorders</td>
</tr>
<tr>
<td class="label">Metabolic Parameter</td>
<td>Normal</td>
</tr>
<tr>
<td class="label">NAD+ levels</td>
<td>Baseline</td>
</tr>
<tr>
<td class="label">SAM/SAH ratio</td>
<td>High</td>
</tr>
<tr>
<td class="label">MNAM levels</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Mitochondrial function</td>
<td>Normal</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>IC50</td>
</tr>
<tr>
<td class="label">JW-7</td>
<td>50 nM</td>
</tr>
<tr>
<td class="label">NAH-1</td>
<td>120 nM</td>
</tr>
<tr>
<td class="label">STL127709</td>
<td>200 nM</td>
</tr>
<tr>
<td class="label">SNP</td>
<td>Location</td>
</tr>
<tr>
<td class="label">rs6942</td>
<td>3'UTR</td>
</tr>
<tr>
<td class="label">rs10842513</td>
<td>Intron</td>
</tr>
<tr>
<td class="label">rs3786194</td>
<td>Promoter</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>NNMT</td>
</tr>
<tr>
<td class="label">Substrate</td>
<td>Nicotinamine</td>
</tr>
<tr>
<td class="label">Product</td>
<td>MNAM</td>
</tr>
<tr>
<td class="label">Brain expression</td>
<td>High</td>
</tr>
<tr>
<td class="label">Disease link</td>
<td>PD, AD</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Normal</td>
</tr>
<tr>
<td class="label">NNMT expression</td>
<td>+</td>
</tr>
<tr>
<td class="label">MNAM levels</td>
<td>+</td>
</tr>
<tr>
<td class="label">NAD+</td>
<td>++</td>
</tr>
<tr>
<td class="label">SAM/SAH ratio</td>
<td>++</td>
</tr>
<tr>
<td class="label">Mitochondrial function</td>
<td>+++</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">NAMPT</td>
<td>Substrate competition</td>
</tr>
<tr>
<td class="label">SIRT1</td>
<td>NAD+ competition</td>
</tr>
<tr>
<td class="label">PARP1</td>
<td>NAD+ competition</td>
</tr>
<tr>
<td class="label">DNMT1</td>
<td>SAH-mediated</td>
</tr>
<tr>
<td class="label">MAT1A</td>
<td>SAM sharing</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>IC50</td>
</tr>
<tr>
<td class="label">5-Methylnicotinamide</td>
<td>μM</td>
</tr>
<tr>
<td class="label">JBSNF-000086</td>
<td>500 nM</td>
</tr>
<tr>
<td class="label">SK-0503</td>
<td>80 nM</td>
</tr>
<tr>
<td class="label">LP-401</td>
<td>45 nM</td>
</tr>
</table>

NNMT (Nicotinamide N-methyltransferase) encodes an enzyme that catalyzes the N-methylation of nicotinamide and other pyridine compounds. This enzyme plays a crucial role in NAD+ metabolism and one-carbon metabolism, with significant implications for neurodegeneration and aging.

Overview

Function

NNMT catalyzes the transfer of a methyl group from S-adenosyl-L-methionine (SAM) to nicotinamide, producing N-methylnicotinamide (MNAM) and S-adenosyl-L-homocysteine (SAH). This reaction is part of the one-carbon metabolism pathway and has several important implications:

• NAD+ metabolite regulation — MNAM is further metabolized to N-methyl-2-pyridone-5-carboxamide (Me2PY) and N-methyl-4-pyridone-5-carboxamide (Me4PY), which are excreted in urine
• One-carbon metabolism — links nicotinamide metabolism to folate and methionine cycles
• Epigenetic regulation — SAH is a potent inhibitor of DNA methyltransferases
• Cellular energetics — affects NAD+ availability for sirtuins and other NAD+-dependent enzymes

Brain Expression

NNMT is expressed in various brain regions:

• Cerebral [cortex](/brain-regions/cortex)
• [Hippocampus](/brain-regions/hippocampus)
• Substantia nigra
• [Cerebellum](/brain-regions/cerebellum)
• [Astrocytes](/entities/astrocytes) and [neurons](/entities/neurons)

Disease Associations

Neurodegenerative Diseases

Parkinson's Disease:

• NNMT activity is elevated in Parkinson's disease brains
• MNAM may have neuroprotective effects by enhancing mitochondrial function
• Altered NAD+ metabolism contributes to dopaminergic neuron vulnerability

• NNMT is upregulated in AD brains
• Changes in one-carbon metabolism affect homocysteine levels
• Linked to [amyloid-beta](/proteins/amyloid-beta) toxicity and [tau](/proteins/tau) pathology

Metabolic Disorders

• Type 2 diabetes
• Non-alcoholic fatty liver disease
• Obesity

Cancer

• Overexpression in multiple cancer types
• Associated with poor prognosis
• Potential therapeutic target

Therapeutic Implications

NNMT modulators are being explored for:

• Neurodegenerative disease treatment
• Cancer therapy
• Metabolic disorder management

Biochemistry and Enzyme Mechanism

NNMT belongs to the class I methyltransferase family and specifically catalyzes the N-methylation of pyridine derivatives including nicotinamide, nicotinic acid, and various xenobiotics[@nicotinamide]. The enzyme utilizes S-adenosyl-L-methionine (SAM) as the methyl donor, producing N-methylnicotinamide (MNAM) and S-adenosyl-L-homocysteine (SAH) as products.

Catalytic Properties

• Substrate specificity: NNMT shows high affinity for nicotinamide (Km ~10-50 μM) but can also methylate structural analogs
• Turnover rate: kcat values range from 0.1-0.5 s⁻¹ depending on substrate
• Inhibition: Product MNAM provides feedback inhibition at higher concentrations
• Cellular localization: Predominantly cytosolic, with some nuclear localization reported

Structural Features

The NNMT protein contains:

• SAM-binding domain characteristic of methyltransferases
• Substrate recognition pocket for pyridine ring
• Dimerization interface for quaternary structure
• Post-translational modification sites (phosphorylation, acetylation)

NNMT in Parkinson's Disease Pathogenesis

Dopaminergic Neuron Vulnerability

NNMT expression is significantly elevated in the substantia nigra of PD patients[@palumbo2021]. Studies using post-mortem brain tissue reveal:

• 2-3 fold increase in NNMT protein levels in dopaminergic neurons
• Correlations between NNMT expression and disease severity
• Association with Lewy body pathology

Mitochondrial Dysfunction

NNMT overexpression in dopaminergic neurons leads to[@williams2022]:

• Impaired complex I activity
• Reduced ATP production
• Increased reactive oxygen species (ROS)
• Disrupted calcium homeostasis

Metabolic Reprogramming

In PD models, NNMT drives a metabolic shift[@yun2022]:

Alpha-Synuclein Interaction

Recent studies demonstrate NNMT's role in alpha-synuclein pathology[@rzhou2023]:

• NNMT expression is induced by alpha-synuclein aggregation
• MNAM can modulate tau phosphorylation pathways
• NNMT inhibition reduces oligomeric alpha-synuclein toxicity
• Cross-talk between NAD+ metabolism and protein aggregation

NNMT in Alzheimer's Disease

Expression Patterns

NNMT is upregulated in AD brain, particularly in[@kelley2020]:

• Hippocampal CA1 region
• Entorhinal cortex
• Frontal cortex
• Around amyloid plaques

Amyloid and Tau Interaction

NNMT affects AD pathophysiology through[matsumoto2023]:

• Modulation of amyloid-beta production and aggregation
• Influence on tau phosphorylation via SAM-dependent methylation
• Effects on neuroinflammation through microglia polarization

One-Carbon Metabolism Link

The connection between NNMT and one-carbon metabolism has implications for[@onecarbon]:

• Homocysteine elevation in AD patients
• DNA methylation abnormalities
• Folate and B-vitamin metabolism
• Vascular contributions to cognitive decline

Neuroinflammation and Glial Cells

Microglia Polarization

NNMT regulates microglial activation states[@liu2022]:

• NNMT+ microglia show pro-inflammatory (M1) phenotype
• CD38 expression correlates with NNMT in neurodegenerative contexts
• NAD+ depletion drives neuroinflammation

Astrocyte Heterogeneity

Single-cell studies reveal NNMT+ astrocyte populations[@xu2023]:

• Age-related increases in NNMT+ astrocytes
• Association with neurovascular unit dysfunction
• Potential therapeutic targeting for astrocyte modulation

Therapeutic Strategies

Small Molecule Inhibitors

Several NNMT inhibitors are in development[hernandez2024]:

Combination Approaches

Combination strategies are being explored[kumar2024]:

• NNMT inhibitors + NAD+ precursors (nicotinamide riboside, NMN)
• NNMT inhibition + sirtuin activators
• NNMT modulation + mitochondrial protectants

N1-Methylnicotinamide (MNAM) as Therapeutic

Despite its role in pathology, MNAM shows neuroprotective potential[goldberg2023]:

• Mitochondrial biogenesis activation
• Anti-inflammatory effects at therapeutic doses
• SIRT1 activation properties
• Clinical translation ongoing

Animal Models

Genetic Models

• NNMT knock-out mice: Viable, showing altered NAD+ metabolism
• NNMT transgenic mice: Develop PD-like phenotypes with age
• AAV-mediated NNMT: Dopaminergic neuron loss in mice

Toxin Models

NNMT modulation affects outcomes in:

• MPTP model of PD
• 6-OHDA lesion model
• Aβ42 overexpression models
• Tauopathy models

Clinical Implications

Biomarker Potential

NNMT and MNAM show promise as[srivastava2024]:

• Diagnostic biomarkers: Serum/CSF levels differentiate PD from controls
• Progression markers: Correlation with disease duration and severity
• Treatment response indicators: Changes with dopaminergic therapy

Clinical Trials

Several trials are investigating NNMT-targeted approaches:

• NAD+ augmentation trials in PD
• Nicotinamide supplementation studies
• SIRT1 activator trials
• Metabolic intervention studies

Genetic Associations

Polymorphisms

NNMT genetic variants have been studied in neurodegeneration:

Expression Quantitative Trait Loci

Brain eQTL studies reveal NNMT expression is regulated by:

• Genetic variants in linkage disequilibrium
• Epigenetic modifications
• Transcription factor networks

Cellular and Molecular Mechanisms

NAD+ Depletion

NNMT activity directly impacts cellular NAD+ pools:

• SAM-dependent methylation consumes methyl groups
• MNAM production leads to downstream metabolites
• Sirtuin activity becomes compromised
• DNA repair mechanisms are affected

Methylation Capacity

The SAH produced[yun2022]:

• Inhibits DNA methyltransferases (DNMTs)
• Affects histone methylation patterns
• Alters RNA methylation (m6A)
• Impacts gene expression broadly

Calcium Dysregulation

NNMT affects calcium homeostasis:

• Mitochondrial calcium buffering impaired
• ER calcium release dysregulated
• Calpain activation increased
• Synaptic transmission compromised

Model Systems

In Vitro Models

• Primary neuron cultures: MPTP-treated, NNMT knockdown
• iPSC-derived neurons: From PD patients[srivastava2024]
• Astrocyte-neuron co-cultures: Metabolic coupling studies
• Organoid models: Brain region-specific

In Vivo Models

• Transgenic mice: Human NNMT overexpression
• Knockout mice: NNMT deletion studies
• Viral models: AAV-NNMT in substantia nigra
• Toxin models: MPTP, 6-OHDA, rotenone

Therapeutic Development Challenges

Blood-Brain Barrier

Brain-penetrant NNMT inhibitors face challenges:

• Molecular weight requirements
• Efflux transporter recognition
• Metabolic stability
• Target engagement metrics

Selectivity

Off-target effects to avoid:

• Other methyltransferases
• S-adenosylhomocysteine hydrolase
• Nicotinamide phosphoribosyltransferase (NAMPT)
• Sirtuin family members

Safety Considerations

Long-term inhibition concerns:

• Peripheral NNMT function
• Liver toxicity
• Cancer risk
• Developmental effects

Comparative Analysis

NNMT vs. Other Methyltransferases

Species Differences

NNMT shows significant species variation:

• Human: Highest brain expression among primates
• Mouse: Lower expression, different isoforms
• Rat: Used in toxicology models
• Zebrafish: Developmental expression

Future Research Directions

Emerging Areas

• Sex-specific effects: NNMT shows gender-dimorphic expression
• Genetic variants: NNMT polymorphisms associated with PD risk
• Multi-omics integration: Systems biology approaches
• Brain regional specificity: Differential effects across brain regions

Unresolved Questions

Interactive Elements

Pathway Diagram

Data Summary Table

Neuroprotection Strategies

Endogenous Neuroprotection

The body has natural mechanisms to counteract NNMT effects:

• Nicotinamide mononucleotide adenylyltransferase (NMNAT): Competes for nicotinamide substrate
• Sirtuin activation: Rescues NAD+-dependent functions
• Autophagy: Clears damaged mitochondria
• Antioxidant systems: Counteracts ROS

Exogenous Interventions

NAD+ Precursors

Nicotinamide riboside (NR) and NMN can bypass NNMT-driven depletion[park2023]:

• NR: 300-1000 mg/day in clinical trials
• NMN: 100-500 mg/day showing safety
• Combination approaches showing synergy
• Blood-brain barrier penetration variable

Methyl Donor Supplementation

SAM supplementation may offset depletion:

• SAMe (S-adenosylmethionine) supplements
• Folate and B-vitamin combinations
• Betaine (trimethylglycine) alternative
• Methionine considerations

Antioxidant Approaches

• CoQ10 and mitochondrial antioxidants
• N-acetylcysteine for glutathione support
• Vitamin E and C supplementation
• Mitochondrial-targeted compounds

Metabolic Syndrome Connection

Type 2 Diabetes

NNMT links neurodegeneration to metabolic disease:

• Elevated NNMT in diabetic brains
• Shared mechanisms with PD/AD
• Insulin signaling interactions
• Therapeutic crossover potential

Obesity

Adipose tissue NNMT affects:

• Systemic NAD+ metabolism
• Inflammation signaling
• Brain-penetrant metabolite effects
• Weight management complications

Non-Alcoholic Fatty Liver Disease

NNMT in liver pathology:

• Hepatic NNMT overexpression
• Methylation capacity exhaustion
• Cardiovascular contributions
• cirrhosis progression risk

Aging Context

Age-Related Changes

NNMT expression naturally increases with age:

• 30-40% elevation by age 70
• Correlates with cognitive decline
• Intersects with senescence pathways
• Contributes to "inflammaging"

Cellular Senescence

NNMT and cellular senescence connection:

• Senescent cells show NNMT elevation
• Senolytic effects on NNMT+ cells
• Secretome effects (SASP)
• Therapeutic implications

Epigenetic Clock

NNMT as aging biomarker:

• Correlates with epigenetic age
• DNA methylation changes
• Potential for rejuvenation
• Biomarker validation

Systems Biology Perspective

Protein-Protein Interactions

NNMT interacts with:

Signaling Pathways

NNMT affects multiple pathways:

• AMPK: Energy sensing, affected by NAD+
• mTOR: Translation, influenced by SAM
• FOXO: Transcription factor regulation
• PGC-1α: Mitochondrial biogenesis
• NF-κB: Inflammation signaling

Metabolic Flux

Nicotinamide metabolic flux:

Nicotinamide → (NAMPT) → NMN → (NMNAT) → NAD+
↓
(NNMT) → MNAM → Me2PY/Me4PY (excretion)
↓
SAM → (NNMT) → SAH → (SAHH) → Homocysteine

Pharmaceutical Development

History of NNMT Inhibitors

Current Pipeline

Major companies in NNMT inhibitor development:

• Novartis: NAD+ metabolism focus
• Roche: CNS indications
• Pfizer: Metabolic disease
• Biotech startups: Several rounds of funding

Formulation Challenges

• Oral bioavailability optimization
• Brain penetration metrics
• Dosing frequency
• Combination therapy compatibility

Diagnostic Applications

Imaging Probes

Developing NNMT-targeted imaging:

• PET tracer development
• Radiosynthesis optimization
• Species selectivity
• Clinical translation

Liquid Biopsy

Serum and CSF biomarkers:

• NNMT protein levels
• MNAM concentrations
• NAD+/NADH ratios
• SAH levels

Digital Health

Wearable integration:

• Activity monitoring correlation
• Metabolic tracking
• Treatment response monitoring
• Disease progression models

Global Health Perspectives

Epidemiology

• PD affects ~10 million worldwide
• AD affects ~55 million globally
• Metabolic diseases affect billions
• Intersection growing

Health Economics

NNMT-related intervention impacts:

• Treatment costs
• Caregiver burden
• Quality of life
• Productivity loss

Resource Allocation

Developing world considerations:

• Diagnostic accessibility
• Treatment affordability
• Infrastructure needs
• Research priorities

Ethical Considerations

Research Ethics

• Informed consent for genetic studies
• Clinical trial accessibility
• Data sharing frameworks
• Animal model welfare

Clinical Ethics

• Off-label use considerations
• Informed decision-making
• Resource allocation justice
• Future access equity

Societal Implications

• Genetic screening debates
• Enhancement considerations
• Privacy concerns
• Healthcare disparities

Summary

NNMT represents a critical node connecting NAD+ metabolism, one-carbon cycling, and neurodegenerative disease pathogenesis. Elevated in both Parkinson's and Alzheimer's disease brains, this enzyme drives metabolic reprogramming that contributes to neuronal vulnerability. The dual nature of NNMT—where both the enzyme and its product MNAM have complex, context-dependent effects—presents both challenges and opportunities for therapeutic targeting. Emerging small molecule inhibitors and combination approaches with NAD+ precursors hold promise for disease-modifying strategies. Biomarker development and validation remain active areas of investigation, with serum and CSF NNMT/MNAM measurements showing diagnostic and prognostic potential. Understanding the precise temporal contributions of NNMT across disease progression will be essential for optimizing intervention strategies. Additionally, recent studies have highlighted NNMT's role in modulating epigenetic aging through DNA methyltransferase inhibition, suggesting potential connections between cellular metabolism and the aging process itself. The enzyme's widespread expression across multiple tissue types and its responsiveness to various metabolic cues make it a dynamic regulator of systemic energy homeostasis. Future research should focus on delineating the cell-type specific functions of NNMT in the brain, particularly in glial cells which outnumber neurons and provide critical support for neuronal survival. The development of brain-penetrant NNMT inhibitors with optimal pharmacokinetic properties remains a key milestone for translating these findings into clinical benefit.

See Also

• [NAD+ Metabolism](/entities/nad-metabolism)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Sirtuins](/entities/sirtuins)
• [Mitochondrial Dynamics](/mechanisms/mitochondrial-dynamics)
• [Neuroinflammation](/mechanisms/neuroinflammation-pathway)
• [One-Carbon Metabolism](/mechanisms/one-carbon-metabolism)

External Links

• [NCBI Gene: NNMT](https://www.ncbi.nlm.nih.gov/gene/4837)
• [UniProt: NNMT](https://www.uniprot.org/uniprot/P40261)
• [OMIM: NNMT](https://www.omim.org/entry/605014)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving NNMT Gene discovered through SciDEX knowledge graph analysis: